Stocks / AMPH vs PAHC

AMPH vs PAHC: Which Stock Is the Better Buy?

Amphastar Pharmaceuticals, Inc. and Phibro Animal Health Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

PAHC is the larger company ($1.3B vs $0.9B). On the fundamentals, AMPH grows revenue faster (15.5% vs 10.1%); AMPH earns a higher net margin (13.6% vs 3.7%); PAHC has the stronger return on equity (16.9% vs 12.4%). On the filings, AMPH carries fewer potential red flags (1 vs 2). Full numbers below — the stronger figure on each row is in green.

AI verdict — AMPH vs PAHC, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 Amphastar Pharmaceuticals, Inc. (AMPH)Phibro Animal Health Corporation (PAHC)
Market cap$0.9B$1.3B
Revenue (latest FY)$719.89M$1.30B
Net income (latest FY)$98.09M$48.30M
Revenue growth (5y CAGR)15.5%10.1%
Net margin13.6%3.7%
Return on equity12.4%16.9%
P/E ratio12.213.6
Dividend yield1.5%
Profitable years (of last 10)910
Positive free cash flowYesYes

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full AMPH vs PAHC breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open AMPH's full financials →   Open PAHC's full financials →

More comparisons

Frequently asked questions

Which is bigger, AMPH or PAHC?

Phibro Animal Health Corporation is larger by market capitalization — $1.3B versus $0.9B.

Which grows faster, AMPH or PAHC?

Over the last five fiscal years, Amphastar Pharmaceuticals, Inc. grew revenue faster — 15.5%/yr versus 10.1%/yr, computed from SEC-filed statements.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

AMPH fundamentals → · PAHC fundamentals → · All 1,500+ companies → · Free screener →